Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 5/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | RHOC | P08134 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | WNT3 | P56703 | 2/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863044 | 1.00 | S1PR2 (0.41) | S1PR2P2RX7ALDH1A1LMNAACP1 | |
| SCHEMBL12005722 | 1.00 | S1PR2 (0.41) | S1PR2P2RX7ALDH1A1LMNAACP1 | |
| SCHEMBL6863181 | 0.94 | S1PR2 (0.41) | S1PR2P2RX7ALDH1A1WNT3SFRP1 | |
| SCHEMBL12015288 | 0.89 | ALDH1A1 (0.40) | S1PR2P2RX7ALDH1A1LMNAACP1 | |
| SCHEMBL12015159 | 0.89 | ALDH1A1 (0.40) | S1PR2P2RX7ALDH1A1LMNAACP1 | |
| SCHEMBL6863132 | 0.89 | S1PR2 (0.40) | S1PR2P2RX7 | |
| SCHEMBL6863244 | 0.89 | S1PR2 (0.40) | S1PR2P2RX7 | |
| SCHEMBL4279470 | 0.85 | EPHX2 (0.45) | P2RX7ALDH1A1LMNAACP1RHOC | |
| SCHEMBL12015290 | 0.85 | EPHX2 (0.45) | P2RX7ALDH1A1LMNAACP1RHOC | |
| SCHEMBL4279471 | 0.85 | EPHX2 (0.45) | P2RX7ALDH1A1LMNAACP1RHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | S1PR2 1046/4885P2RX7 526/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.